摘要
目的:探讨阿仑膦酸钠联合碳酸钙及骨化三醇治疗方案在围绝经期骨质疏松症临床效果.方法:回顾性收集本院2019年1月-2020年9月收治的115例围绝经期骨质疏松患者临床资料,根据治疗方案分为对照组(碳酸钙及骨化三醇治疗)56例和观察组(阿仑膦酸钠联合碳酸钙及骨化三醇治疗)59例.分析两组治疗疗效,骨代谢相关指标、骨密度变化以及用药后不良反应.结果:治疗1年后,观察组临床总有效率(86.4%)高于对照组(71.4%),腰椎(0.88±0.09g/cm^(2))、股骨颈(0.78±0.12g/cm^(2))及股骨粗隆间(0.86±0.14g/cm^(2))骨密度均高于对照组(0.84±0.12 g/cm^(2)、0.19±0.03g/cm^(2)、0.81±0.11g/cm^(2)),两组血清骨钙素、β-I型胶原羧基端肽水平较有所下降,骨源性碱性磷酸酶水平均有所上升,但观察组变化幅度高于对照组(均P<0.05);观察组不良反应发生率(5.1%)与对照组(1.8%)无差异(P>0.05).结论:阿仑膦酸钠联合碳酸钙及骨化三醇治疗方案可更好地改善女性骨代谢指标及骨密度,明显提高临床疗效,且用药安全性.
Objective: To explore the clinical effect of alendronate sodium combined with calcium carbonate and calcitriol for treating perimenopausal patients with osteoporosis.Methods:The clinical data of 115 perimenopausal patients with osteoporosis between January 2019 and September 2020 were collected retrospectively.According to the treatment regimens,these patients were divided into control group(56 cases with the treatment of calcium carbonate and calcitriol)and observation group(59 cases with the treatment of alendronate sodium combined with calcium carbonate and calcitriol).The therapeutic efficacy,the changes of bone metabolism-related indicators and bone mineral density(BMD),and the adverse reactions rate of the patients in the two groups after medication were analyzed.Results:The total effective rate(86.4%)of the patients in the observation group after 1 year of treatment was significantly higher than that(71.4%)of the patients in the control group.The values of BMD of lumbar spine(0.88±0.09g/cm^(2)),femoral neck(0.78±0.12 g/cm^(2)),and intertrochanteric femur(0.86±0.14 g/cm^(2))of the patients in the observation group were significantly higher than those(0.84±0.12 g/cm^(2),0.19±0.03 g/cm^(2),and 0.81±0.11 g/cm^(2))of the patients in the control group.The levels of serum osteocalcin andβ-I collagen carboxyl terminal peptide of the patients in the two groups after treatment had decreased significantly,and the level of bone-derived alkaline phosphatase of the patients in the two groups had increased significantly,and the changes of which of the patients in the observation group were significantly higher than those of the patients in the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions(5.1%vs.1.8%)of the patients between the two groups(P>0.05).Conclusion:Alendronate sodium combined with calcium carbonate and calcitriol therapy of the perimenopausal patients with osteoporosis can improve their bone metabolism indicators and bone mineral density betterly,and can significantly increase their clinical efficacy with safety of treatment.
作者
何欣
黄玉琴
HE Xin;HUANG Yuqin(Suining Central Hospital,Sichuan Province,629000;People’s Hospital of Yilong County,Nanchong,Sichuan Province)
出处
《中国计划生育学杂志》
2022年第10期2365-2368,2373,共5页
Chinese Journal of Family Planning
基金
四川省自贡市科学技术局重点项目(2020YLSF10)。
关键词
围绝经期骨质疏松症
骨代谢
阿仑膦酸钠
碳酸钙
骨化三醇
Perimenopausal osteoporosis
Bone metabolism
Alendronate sodium
Calcium carbonate
Calcitriol
